Merck's Pifeltro (doravirine) Receives FDA Approval for Patients with HIV-1 in Appropriate Patients
Shots:
- The approval is based on P-III DRIVE-FORWARD study assessing Pifeltro (qd) vs darunavir + ritonavir (DRV+r) (800mg- 100 mg- qd) each in combination with emtricitabine (FTC)/TDF or abacavir (ABC)/3TC in patients with HIV-1 infection
- P-III DRIVE-FORWARD study results: @48 wks. viral suppression of HIV-1 RNA <40 copies/mL (83% vs 79%); @96 wks. (72% vs 64%); patients discontinued treatment (2% vs 3%) ; LDL-cholesterol and non-HDL-cholesterol (-4.6--5.4 mg/DL vs 9.5- 13.7 mg/DL)
- Pifeltro (doravirine- 100mg) is a qd NNRTI in combination with antiretroviral medicines indicated and approved for the HIV-1 infection
Ref: Merck | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com